Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Treatment and prognosis of myocarditis in adults

Leslie T Cooper, Jr, MD
Section Editor
William J McKenna, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC


Myocarditis refers to inflammation of the heart muscle. The diagnosis may be suspected by clinical and noninvasive features and is confirmed by histopathologic criteria on endomyocardial biopsy. The clinical manifestations of this disorder vary greatly from asymptomatic changes on an electrocardiogram to fulminant heart failure (HF). (See "Clinical manifestations and diagnosis of myocarditis in adults".)

This topic will review the prognosis and treatment of myocarditis in adults. Treatment of myocarditis consists of both specific therapy aimed at the cause of the myocarditis and nonspecific therapy aimed at the clinical manifestations such as HF and arrhythmias. The etiology, incidence, pathogenesis, clinical manifestations, and diagnosis of myocarditis are discussed separately. (See "Etiology and pathogenesis of myocarditis" and "Clinical manifestations and diagnosis of myocarditis in adults".)

A significant minority of patients with pericarditis also have myocarditis. Myocarditis associated with pericarditis, including vaccinia-associated disease (myocarditis and/or pericarditis), is discussed separately. (See "Myopericarditis".)


Variable disease course — The course of myocarditis varies with the presenting clinical syndrome.

The prevalence and outcomes of myocarditis in community-based populations are unknown. However, seroepidemiologic studies suggest that the majority of cases of Coxsackie B virus infection are subclinical and have a benign course [1].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 28, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. O'Connell, JB. Diagnosis and medical treatment of inflammatory cardiomyopathy. In: Cardiovascular Medicine, Topol, E, Nissen, J (Eds), Lippincott-Raven, Philadelphia 1998.
  2. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.
  3. Wentworth P, Jentz LA, Croal AE. Analysis of sudden unexpected death in southern Ontario, with emphasis on myocarditis. Can Med Assoc J 1979; 120:676.
  4. Imazio M, Brucato A, Barbieri A, et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation 2013; 128:42.
  5. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333:269.
  6. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007; 28:1326.
  7. Grün S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012; 59:1604.
  8. Magnani JW, Danik HJ, Dec GW Jr, DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J 2006; 151:463.
  9. Hosenpud JD, McAnulty JH, Niles NR. Unexpected myocardial disease in patients with life threatening arrhythmias. Br Heart J 1986; 56:55.
  10. Krahn AD, Healey JS, Chauhan V, et al. Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). Circulation 2009; 120:278.
  11. Sekiguchi M, Nishizawa M, Nunoda S, et al. Endomyocardial biopsy approach in cases with ventricular arrhythmias. Postgrad Med J 1992; 68 Suppl 1:S40.
  12. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180.
  13. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27:136.
  14. Miklozek CL, Kingsley EM, Crumpaker CS, et al. Serial cardiac function tests in myocarditis. Postgrad Med J 1986; 62:577.
  15. Kearney MT, Cotton JM, Richardson PJ, Shah AM. Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J 2001; 77:4.
  16. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001; 104:1076.
  17. Caforio AL, Goldman JH, Haven AJ, et al. Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. The Myocarditis Treatment Trial Investigators. Eur Heart J 1997; 18:270.
  18. Lauer B, Schannwell M, Kühl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000; 35:11.
  19. Caforio AL, Vinci A, Iliceto S. Anti-heart autoantibodies in familial dilated cardiomyopathy. Autoimmunity 2008; 41:462.
  20. Grogan M, Redfield MM, Bailey KR, et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995; 26:80.
  21. Goldberg RJ, Suk J, Patton KK, et al. Predictors of adverse outcome in biopsy-proven myocarditis (abstract). J Am Coll Cardiol 1999; 33:A850.
  22. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342:690.
  23. Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002; 105:1663.
  24. Ammirati E, Cipriani M, Lilliu M, et al. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 2017; 136:529.
  25. Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 2000; 36:227.
  26. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965.
  27. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107:857.
  28. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118:639.
  29. Fuse K, Kodama M, Okura Y, et al. Predictors of disease course in patients with acute myocarditis. Circulation 2000; 102:2829.
  30. Sheppard R, Bedi M, Kubota T, et al. Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol 2005; 46:1036.
  31. Nishii M, Inomata T, Takehana H, et al. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 2004; 44:1292.
  32. McNamara DM, Starling RC, Cooper LT, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol 2011; 58:1112.
  33. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997; 336:1860.
  34. Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013; 6:15.
  35. Cooper LT, Zehr KJ. Biventricular assist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis. Nat Clin Pract Cardiovasc Med 2005; 2:544.
  36. Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611.
  37. Milisavljević N, Cvetković M, Nikolić G, et al. Dilated cardiomyopathy associated with celiac disease: case report and literature review. Srp Arh Celok Lek 2012; 140:641.
  38. Curione M, Barbato M, De Biase L, et al. Prevalence of coeliac disease in idiopathic dilated cardiomyopathy. Lancet 1999; 354:222.
  39. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34:2636.
  40. Rezkalla S, Kloner RA, Khatib G, Khatib R. Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis. Am Heart J 1990; 120:1377.
  41. Tominaga M, Matsumori A, Okada I, et al. Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice. Circulation 1991; 83:2021.
  42. Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J 1999; 63:934.
  43. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012; 59:779.
  44. Rockman HA, Adamson RM, Dembitsky WP, et al. Acute fulminant myocarditis: long-term follow-up after circulatory support with left ventricular assist device. Am Heart J 1991; 121:922.
  45. Chen JM, Spanier TB, Gonzalez JJ, et al. Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance. J Heart Lung Transplant 1999; 18:351.
  46. Atluri P, Ullery BW, MacArthur JW, et al. Rapid onset of fulminant myocarditis portends a favourable prognosis and the ability to bridge mechanical circulatory support to recovery. Eur J Cardiothorac Surg 2013; 43:379.
  47. Boehmer JP, Starling RC, Cooper LT, et al. Left ventricular assist device support and myocardial recovery in recent onset cardiomyopathy. J Card Fail 2012; 18:755.
  48. O'Connell JB, Dec GW, Goldenberg IF, et al. Results of heart transplantation for active lymphocytic myocarditis. J Heart Transplant 1990; 9:351.
  49. O'Connell JB, Breen TJ, Hosenpud JD. Heart transplantation in dilated heart muscle disease and myocarditis. Eur Heart J 1995; 16 Suppl O:137.
  50. Moloney ED, Egan JJ, Kelly P, et al. Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant 2005; 24:1103.
  51. European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.
  52. Prochnau D, Surber R, Kuehnert H, et al. Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction. Clin Res Cardiol 2010; 99:129.
  53. Costanzo-Nordin MR, Reap EA, O'Connell JB, et al. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol 1985; 6:1078.
  54. Rezkalla S, Khatib G, Khatib R. Coxsackievirus B3 murine myocarditis: deleterious effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 1986; 107:393.
  55. Khatib R, Reyes MP, Smith F, et al. Enhancement of coxsackievirus B4 virulence by indomethacin. J Lab Clin Med 1990; 116:116.
  56. Miller, H, Abelmann, WH. Effects of dietary ethanol upon experimental Trypanosomal (T. cruzi) myocarditis. Proc Soc Exp Biol Med 1967; 126:193.
  58. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation 2015; 132:e273.
  59. Rose NR, Neumann DA, Herskowitz A. Coxsackievirus myocarditis. Adv Intern Med 1992; 37:411.
  60. Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 1988; 12:1334.
  61. Kishimoto C, Crumpacker CS, Abelmann WH. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D. Cardiovasc Res 1988; 22:732.
  62. Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 1988; 115:1229.
  63. Yamamoto N, Shibamori M, Ogura M, et al. Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus. Circulation 1998; 97:1017.
  64. Daliento L, Calabrese F, Tona F, et al. Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant 2003; 22:214.
  65. Coletta AP, Clark AL, Cleland JG. Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA. Eur J Heart Fail 2009; 11:214.
  66. Schultheiss, HF, Noutsias M, et al. Antiviral interferon-β treatment in patients with chronic viral cardiomyopathy. In: Inflammatory Cardriomyopathy (DCMi); Progress in Inflammation Research, Springer, 2010.
  67. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30:1995.
  68. Padalko E, Verbeken E, Matthys P, et al. Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol 2003; 3:25.
  69. Tomioka N, Kishimoto C, Matsumori A, Kawai C. Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol 1986; 7:868.
  70. Monrad ES, Matsumori A, Murphy JC, et al. Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus. Circulation 1986; 73:1058.
  71. Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev 2013; :CD004471.
  72. Mason JW, Billingham ME, Ricci DR. Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol 1980; 45:1037.
  73. Jones SR, Herskowitz A, Hutchins GM, Baughman KL. Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function. Am J Cardiol 1991; 68:370.
  74. Maisch B, Schönian U, Hengstenberg C, et al. Immunosuppressive treatment in autoreactive myocarditis--results from a controlled trial. Postgrad Med J 1994; 70 Suppl 1:S29.
  75. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103:2254.
  76. O'Connell JB, Mason JW. Diagnosing and treating active myocarditis. West J Med 1989; 150:431.
  77. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104:39.
  78. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation 2006; 113:593.
  79. Parrillo JE. Inflammatory cardiomyopathy (myocarditis): which patients should be treated with anti-inflammatory therapy? Circulation 2001; 104:4.
  80. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation 2006; 113:876.
  81. Müller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101:385.
  82. Wallukat G, Müller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347:1806.
  83. Staudt A, Böhm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002; 106:2448.
  84. Staudt A, Dörr M, Staudt Y, et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 2005; 150:729.
  85. Vignola PA, Aonuma K, Swaye PS, et al. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 1984; 4:812.
  86. Robinson JL, Hartling L, Crumley E, et al. A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord 2005; 5:12.
  87. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103:220.
  88. Cooper LT Jr, Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102:1535.
  89. Litovsky SH, Burke AP, Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996; 9:1126.
  90. Menghini VV, Savcenko V, Olson LJ, et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc 1999; 74:1221.
  91. Kawano S, Kato J, Kawano N, et al. Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period. Intern Med 2011; 50:975.
  92. Dong R, Liu P, Wee L, et al. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest 1992; 90:2022.
  93. Yamada T, Matsumori A, Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994; 89:846.
  94. Kishimoto C, Takada H, Hiraoka Y, Shiraki K. Effects of naloxone, an opiate receptor antagonist, on coxsackievirus B3 myocarditis in the mouse. Cardiovasc Res 1995; 29:80.
  95. Wang Y, Afanasyeva M, Hill SL, et al. Nasal administration of cardiac myosin suppresses autoimmune myocarditis in mice. J Am Coll Cardiol 2000; 36:1992.
  96. Liu JP, Yang M, Du XM. Herbal medicines for viral myocarditis. Cochrane Database Syst Rev 2004; :CD003711.
  97. Cao Y, Xu X, Zhang P. Advances in the Traditional Chinese Medicine-Based Management of Viral Myocarditis. Cell Biochem Biophys 2015; 73:237.
  98. Murphy JG, Wright RS, Bruce GK, et al. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet 2003; 362:1378.
  99. Dec GW Jr, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985; 312:885.
  100. Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus. Circulation 2009; 119:2615.